Science has raised a $400 million Series D financing with participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech, among others. This brings the total capital raised since our founding in 2021 to more than $900 million.
This round comes a few months after our European commercial launch of PRIMA, the first brain-computer interface to be CE marked to restore form vision—the ability to read letters, numbers, and words—for patients blinded by certain types of late-stage macular degeneration.
We’ll use the new capital to accelerate PRIMA’s availability across Europe and to prepare for its launch in the United States, where we’re pursuing FDA approval through the Humanitarian Device Exemption pathway. We’ll also expand our research, manufacturing, and operational infrastructure, and make substantial further investments in our biohybrid program, a neural interface that integrates engineered neurons with the brain’s own circuits.